Keros Therapeutics (KROS) Net Income towards Common Stockholders (2019 - 2025)
Keros Therapeutics (KROS) reported Net Income towards Common Stockholders of -$23.5 million for Q4 2025, up 49.03% on a YoY basis from -$15.7 million in Q4 2024, and down 222.27% quarter-over-quarter from -$7.3 million in Q3 2025.
Keros Therapeutics (KROS) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$23.5 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 49.03% year-over-year to -$23.5 million; the trailing twelve-month figure through Dec 2025 stood at $87.0 million (up 146.44% YoY), and the FY2025 full-year result was $87.0 million, up 146.44% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$23.5 million, down from -$7.3 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $148.5 million in Q1 2025, with the low at -$53.0 million in Q3 2024.
- Historically, Net Income towards Common Stockholders has averaged -$20.8 million across 5 years, with a median of -$28.5 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 328.21% — and 2025, when it jumped 444.32%.
- Keros Therapeutics' Net Income towards Common Stockholders stood at -$6.9 million in 2021, then sank by 328.21% to -$29.7 million in 2022, then sank by 35.42% to -$40.2 million in 2023, then slipped by 14.37% to -$46.0 million in 2024, then soared by 49.03% to -$23.5 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -23.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.46 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -30.70 Mn |
| Mar 31, 2025 | 148.45 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -40.24 Mn |
| Sep 30, 2023 | -39.44 Mn |
| Jun 30, 2023 | -37.51 Mn |
| Mar 31, 2023 | -35.80 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -6.94 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -15.62 Mn |
| Mar 31, 2021 | -15.89 Mn |